Hampl J, Chien Y H, Davis M M
The Howard Hughes Medical Institute, Stanford University School of Medicine, California 94305, USA.
Immunity. 1997 Sep;7(3):379-85. doi: 10.1016/s1074-7613(00)80359-3.
The recognition of peptide variants by the T cell receptor (TCR) has revealed a wide range of possible responses. Here, using a series of CD4+ and CD4- variants of the same T cell hybridoma, we find that while the expression of CD4 converts weak agonists into full agonists, none of the antagonist peptides are efficiently recognized as agonists. Furthermore, in antagonist assays, little difference can be seen in the response of CD4+ and CD4- T cells. Together with previous work showing a marked difference in stability between TCR binding to agonist versus antagonist ligands, these data suggest that CD4 engagement occurs after a TCR-peptide/MHC complex has formed and that it requires a certain minimal half-life of the ternary complex to be fully engaged in signaling.
T细胞受体(TCR)对肽变体的识别揭示了广泛的可能反应。在此,我们使用同一T细胞杂交瘤的一系列CD4 +和CD4 -变体,发现虽然CD4的表达将弱激动剂转化为完全激动剂,但没有一种拮抗剂肽能被有效地识别为激动剂。此外,在拮抗剂检测中,CD4 +和CD4 - T细胞的反应几乎没有差异。结合之前显示TCR与激动剂和拮抗剂配体结合稳定性存在显著差异的研究,这些数据表明CD4的参与发生在TCR-肽/MHC复合物形成之后,并且它需要三元复合物具有一定的最短半衰期才能完全参与信号传导。